HUMA (Humacyte) Total Current Liabilities : $20.94 Mil (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Humacyte Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Humacyte's total current liabilities for the quarter that ended in Sep. 2024 was $20.94

Humacyte Total Current Liabilities Historical Data

The historical data trend for Humacyte's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Humacyte Total Current Liabilities Chart

Humacyte Annual Data

Trend Dec20 Dec21 Dec22 Dec23

Total Current Liabilities

11.23 11.05 19.58 18.44

Humacyte Quarterly Data

Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24

Total Current Liabilities Get a 7-Day Free Trial 15.14 18.44 14.09 17.76 20.94

Humacyte Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Humacyte's Total Current Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Liabilities = Accounts Payable & Accrued Expense + Short-Term Debt & Capital Lease Obligation

= 10.592 + 2.613

+ Other Current Liabilities + Current Deferred Liabilities

= 5.238 + 0

= 18.44

Humacyte's Total Current Liabilities for the quarter that ended in Sep. 2024 is calculated as

Total Current Liabilities = Accounts Payable & Accrued Expense + Short-Term Debt & Capital Lease Obligation

= 11.713 + 2.888

+ Other Current Liabilities + Current Deferred Liabilities

= 6.341 + 0

= 20.94

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Humacyte Total Current Liabilities Related Terms
Thank you for viewing the detailed overview of Humacyte's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Humacyte Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Humacyte Inc (NAS:HUMA) » Definitions » Total Current Liabilities

Comparable Companies

ZURA ARQT ATAI EPIX LCTX RENB AEON XOMA FATE IMRX OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX

Traded in Other Exchanges

N/A

Address

2525 East North Carolina Highway 54, Durham, NC, USA, 27713

Website

https://www.humacyte.com

Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions.

Executives

Michael T. Constantino director C/O 9 METERS BIOPHARMA, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH NC 27615

Laura E Niklason director, 10 percent owner, officer: President, CEO and Director 35 WILSHIRE ROAD, GREENWICH CT 06831

Brady W Dougan director, 10 percent owner 35 WILSHIRE ROAD, GREENWICH CT 06831

Kathleen Sebelius director C/O DERMIRA, INC., 275 MIDDLEFIELD ROAD, SUITE 150, MENLO PARK CA 94025

Dale A. Sander officer: CFO & CCDO 11304 EMPIRE LAKES DRIVE, RALEIGH NC 27617

Heather Ledbetter Prichard officer: Chief Operating Officer 820 BROWNWICH STREET, WAKE FOREST NC 27587

Max N. Wallace director 210 WEST TRYON STREET, HILLSBOROUGH NC 27278

Gordon M Binder director 225 S. LAKE AVE., SUITE 300, PASADENA CA 91101

Ayabudge Llc 10 percent owner 35 WILSHIRE ROAD, GREENWICH CT 06831

William John Scheessele officer: Chief Commercial Officer 620 WADE AVENUE, UNIT 501, RALEIGH NC 27605

Yang Cao officer: Chief Regulatory Officer 12 DOGLEG LANE, LAWRENCE NJ 08648

Charles Bruce Green director 3185 SCENIC DRIVE, NAPA CA 94558

Diane Seimetz director JUTASTRASSE, MUNICH 2M 80636

Shamik J Parikh officer: Chief Medical Officer 1160 HEDGEROW DRIVE, GARNET VALLEY PA 19060

Rajiv Shukla director EMERALD VIEW SUITE 400, 2054 VISTA PARKWAY, WEST PALM BEACH FL 33411

Humacyte Headlines

From GuruFocus

Kirby McInerney LLP Reminds Humacyte (HUMA) Investors of Class Action Filing and Encourages Investors to Contact the Firm
By Business Wire • 12-02-2024

Shareholders of Humacyte, Inc. Should Contact Levi & Korsinsky Before January 17, 2025 to Discuss Your Rights - HUMA
By PRNewswire • 12-02-2024

HUMA Investors Have Opportunity to Lead Humacyte, Inc. Securities Fraud Lawsuit
By PRNewswire • 12-02-2024

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Humacyte, Inc. (HUMA)
By Marketwired • 12-03-2024

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of January 17, 2025 in Humacyte, Inc. Lawsuit - HUMA
By PRNewswire • 12-05-2024

ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HUMA
By Marketwired • 12-03-2024

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte
By Marketwired • 12-03-2024

Robbins LLP Urges HUMA Stockholders with Large Losses to Contact the Firm for Information About the Humacyte, Inc. Class Action Lawsuit
By Marketwired • 12-03-2024

HUMA Investors Have Opportunity to Lead Humacyte, Inc. Securities Fraud Lawsuit
By PRNewswire • 12-01-2024

DEADLINE ALERT for HUMA, XRX, and ZETA: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
By Marketwired • 12-04-2024

Humacyte Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Current Liabilities	Get a 7-Day Free Trial												15.14	18.44	14.09	17.76	20.94

Total Current Liabilities	=	Accounts Payable & Accrued Expense	+	Short-Term Debt & Capital Lease Obligation
	=	10.592	+	2.613
	+	Other Current Liabilities	+	Current Deferred Liabilities
	=	5.238	+	0
	=	18.44

Michael T. Constantino	director	C/O 9 METERS BIOPHARMA, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH NC 27615
Laura E Niklason	director, 10 percent owner, officer: President, CEO and Director	35 WILSHIRE ROAD, GREENWICH CT 06831
Brady W Dougan	director, 10 percent owner	35 WILSHIRE ROAD, GREENWICH CT 06831
Kathleen Sebelius	director	C/O DERMIRA, INC., 275 MIDDLEFIELD ROAD, SUITE 150, MENLO PARK CA 94025
Dale A. Sander	officer: CFO & CCDO	11304 EMPIRE LAKES DRIVE, RALEIGH NC 27617
Heather Ledbetter Prichard	officer: Chief Operating Officer	820 BROWNWICH STREET, WAKE FOREST NC 27587
Max N. Wallace	director	210 WEST TRYON STREET, HILLSBOROUGH NC 27278
Gordon M Binder	director	225 S. LAKE AVE., SUITE 300, PASADENA CA 91101
Ayabudge Llc	10 percent owner	35 WILSHIRE ROAD, GREENWICH CT 06831
William John Scheessele	officer: Chief Commercial Officer	620 WADE AVENUE, UNIT 501, RALEIGH NC 27605
Yang Cao	officer: Chief Regulatory Officer	12 DOGLEG LANE, LAWRENCE NJ 08648
Charles Bruce Green	director	3185 SCENIC DRIVE, NAPA CA 94558
Diane Seimetz	director	JUTASTRASSE, MUNICH 2M 80636
Shamik J Parikh	officer: Chief Medical Officer	1160 HEDGEROW DRIVE, GARNET VALLEY PA 19060
Rajiv Shukla	director	EMERALD VIEW SUITE 400, 2054 VISTA PARKWAY, WEST PALM BEACH FL 33411